Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS387 in advanced solid tumors
NCT07092748Phase 1Recruiting
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS387 in solid tumor (advanced stage), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoints: Number of Participants Reporting Adverse Events (AEs) or Serious Adverse Events (SAEs) at 2 years and Dose-limiting Toxicities Incidence Count Among Study Participant at 2 years. Started Jul 2025; status: recruiting.
02
Drugs
HS387
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07092748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07092748.